Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppressesEGFRmutant non-small cell lung cancer growthin vitroandin vivo
Open Access
- 8 December 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (1) , 995-1013
Abstract
Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivoKeywords
This publication has 67 references indexed in Scilit:
- Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesisThe Journal of Steroid Biochemistry and Molecular Biology, 2013
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor ResistanceClinical Cancer Research, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- CYP24 inhibition preserves 1α,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cellsMolecular and Cellular Endocrinology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProceedings of the National Academy of Sciences, 2010
- Quantitative determination of vitamin D metabolites in plasma using UHPLC-MS/MSAnalytical and Bioanalytical Chemistry, 2010
- The Number of Vitamin D Receptor Binding Sites Defines the Different Vitamin D Responsiveness of the CYP24 Gene in Malignant and Normal Mammary CellsJournal of Biological Chemistry, 2010
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004